



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

### Summary of Main Points from the Meeting held on Monday 27<sup>th</sup> July 2020

#### **2. Minutes and Summary Notes from last meeting**

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Zoom. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda for September 2020.

#### **3. Matters Arising**

The Group noted the matters arising from the previous meeting.

#### **4. Business to be transacted by the Medicines Group**

##### **a) Formulary Applications**

##### ***Full Applications***

##### **Melatonin 1mg & 5mg Prolonged-Release Tablets (Slenyto®)**

Requested by Paediatrics for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

This is the only licenced preparation for use in Paediatrics. Many patients with disorders such as autism struggle with the liquid preparation and would benefit from the mini pill option which can be hidden in food to increase compliance.

Paediatric expect 20 patients to be treated at each hospital site who would benefit from switching from liquid melatonin to Slenyto®.

Melatonin liquid (Colonis®) (£0.87/mg) vs Melatonin (Slenyto®) (£0.45/mg)

**Outcome: Additional information to be sought to support the decision**

##### **Medroxyprogesterone Acetate (MPA) 104mg in 0.65ml suspension for Injection (Sayana-Press®)**

Requested by GUM for its licensed indication for long-term female contraception.

Sayana-Press® is administered by subcutaneous injection (one injection per 13 weeks) thereby facilitating self-administration at home, enhancing patient experience and reducing hospital clinic time.

Having this available as an option will help with the management of appointments during the Covid Pandemic period.

Sayana-Press® is not currently included on the NWLIF and therefore it would be expected that an application is made to the panel for its inclusion, to increase flexibility for women should they subsequently wish to obtain contraceptives via their GP.

Cost comparison:

- Sayana-Press® (Medroxyprogesterone Acetate 105mg/0.65ml Injection (SC every 13 weeks) - £6.90 per Injection
- Depo-Provera® (Medroxyprogesterone Acetate 150mg/ml Injection (IM every 12 weeks) - £6.10 per Injection

**Outcome: Approved for addition to the formulary**

***Ex-panel***



### **Daratumumab (Darzalex®) 1,800mg Solution for Injection**

This is a new SC product presented as a 1800 mg of daratumumab solution for subcutaneous injection. The dosing schedule will vary according to the indication, but this remains the same as per the IV dosing schedule for each indication.

For use in line with the following NICE Technology Appraisals for daratumumab which include a recommended dose schedule using 16mg/kg body weight by intravenous (IV) infusion.

- Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. Technology appraisal guidance (TA573)
- Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. Technology appraisal guidance (TA510)

Both treatments are funded from the Cancer Drugs Fund (CDF). NHS England and NHS Improvement can confirm that the new SC Daratumumab product will be funded within the NHS provided it remains a cost neutral alternative to the IV formulation.

New patients may be initiated on the SC version as an alternative to the IV formulation following discussion between the individual patients and their clinician. Patients currently receiving IV daratumumab can be switched to SC daratumumab following the advice in the manufacturer's SPC. Approved for addition to the formulary by Chair's action on 06/07/2020 - For noting

**Outcome: Noted**

### **Human Papillomavirus 9-Valent Vaccine (Gardasil 9®)** **Deferred to next meeting**

#### **Removals**

- Nil

#### **NICE Approved drug applications**

- **TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer**  
Approved by NICE in May 2020

**Outcome: Approved for addition to the formulary**

- **TA631 - Fremanezumab for preventing migraine**  
Approved by NICE in June 2020

**Outcome: Approved for addition to the formulary**

#### **Pharmacoeconomic Board requests**

- Nil

#### **4.2 Trust Medicines Policy**

- **TMP: Section 21: Patient Group Directions**

- Full review and update undertaken
- Addition of:
  - Approval process for PGDs used by services externally contracted by the Trust
  - Supply of medicines under PGD by posting or where the patient is absent

**Outcome: Approved**

- **Updates to Trust Adult IV Administration Guide**

- Update to the Fosfomycin IV monograph to include reconstitution/dilution instructions as now diluting in IV fluid bag rather than hanging a pre-diluted glass bottle.
- New Monograph: Ocrelizumab (Ocrevus®)

**Outcome: Approved**



#### **4.3 Medicines Optimisation**

- **Trust Medicines Optimisation Annual Report 2019/20**

Medicines optimisation encompasses a range of activities intended to improve the way that medicines are selected, procured, prescribed, dispensed and administered.

This report summarises the activities of groups responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust, describes developments throughout the 2019-20 year and reports on results of external assessments and peer reviews.

**Action: Group members to review and forward any comments or suggestions for change to DR by 7<sup>th</sup> August 2020**

#### **4.4 NICE Technical Appraisals and Guidance**

**a) NICE Technical Appraisals**

**1 Appraisal published in May 2020 since last meeting**

**8 Appraisals published in June 2020**

**2 Appraisals published in July 2020**

**TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure**

**Recommendations**

**Formulary status / Action**

**Add to the formulary following receipt of a signed application form from the Hepatology Team.**

**TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours**

**Formulary status / Action**

**Not applicable - CWFT not commissioned**

**Action: To be queried with NHS England as it would be expected that CWFT is a commissioned site.**

**TA631 - Fremanezumab for preventing migraine**

**Formulary status / Action**

**Added to the formulary following receipt of a signed application form from the Neurology Team - See Section 4.1**

**TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer**

**Formulary status / Action**

**Currently included on the formulary.**

**Numbers likely to treat at CWH site: 0 patients per year - Condition not treated at CW site**

**Numbers likely to treat at WMUH site: 4-6 patients per year**

**TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis**

**Formulary status / Action**

**Currently included on the formulary.**

**Numbers likely to treat at CWH site: 15 patients per year**

**Numbers likely to treat at WMUH site: 6 patients per year**

**TA634 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma**

**Formulary status / Action**

**Nil - Terminated appraisal**

**TA635 - Eculizumab for treating refractory myasthenia gravis (Terminated appraisal)**

**Formulary status / Action**

**Nil - Terminated appraisal**



**TA636 - Eculizumab for treating refractory myasthenia gravis (Terminated appraisal)**

**Formulary status / Action**

**Nil - Terminated appraisal**

**TA637 - Ranibizumab for treating diabetic retinopathy (Terminated appraisal)**

**Formulary status / Action**

**Nil - Terminated appraisal**

**TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer**

**Formulary status / Action**

**Currently included on the formulary.**

**Numbers likely to treat at CWH site: 5-6 patients per year**

**Numbers likely to treat at WMUH site: 0 patients per year - Condition not treated at WMUH site**

**TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer**

**Formulary status / Action**

**Currently atezolizumab included on the formulary for other indication.**

**Numbers likely to treat at CWH site: 0 patients per year - Condition not treated at CW site**

**Numbers likely to treat at WMUH site: 3-5 patients per year**

**Add nab-paclitaxel to the formulary following receipt of a signed application form from the WM Oncology Team.**

**a) NICE Highly Specialised Technologies published since last meeting**

**0 Highly Specialised Technologies published**

**4.5 IVIG requests**

**• IVIG Issues for May 2020 - WMUH Site**

There were 12 IVIG issues in May 2020, with 8 new requests:

**Outcome: Noted**

**• IVIG Issues for June 2020 - CWH Site**

There were 8 IVIG issues in June 2020, with 4 new requests:

**Outcome: Noted**

**• IVIG Issues for June 2020 - WMUH Site**

**Outcome: Noted**

**4.6 Items for noting**

**• Medication Safety Bulletin - National Patient Safety Review of Medication-related incidents**

Medication safety Bulletin relating to National Patient Safety Review of Medication - Related Incidents published July 2020

**Outcome: Noted**

**• Patient Group Directions Log - July 2020**

Patient Group Directions Log for July 2020

**Outcome: Noted**

**• NWL moving to single CCG**



Letter from NWL providing an update on NWL moving to single CCG by April 2021

**Outcome: Noted**

- **MHRA Drug Safety Update - June 2020**

MHRA update for June 2020

**Outcome: Noted**

**4.7 Meeting minutes for noting**

- Nil

**4.8 Additional papers to go to Trust Patient Safety Group**

- Trust Medicines Optimisation Annual Report 2019/20

**5. Any other business**

- Nil

**6. Date of next meeting**

**Date: 28<sup>th</sup> September**

**Time: 8am-9am**

**Location: Via Zoom**

**Closing date: 11<sup>th</sup> September 2020**